104236-78-4

Usage

Uses

Used in Pharmaceutical Industry:
2',4'-DIHYDROXY-2-METHOXYCHALCONE is used as a potential therapeutic agent for its ability to inhibit the growth of cancer cells. It has been studied for its potential to treat various types of cancer due to its anti-proliferative and pro-apoptotic effects on cancer cells.
Used in Anti-Diabetic Applications:
2',4'-DIHYDROXY-2-METHOXYCHALCONE is used as a potential anti-diabetic agent, as research has shown its ability to improve insulin sensitivity and glucose metabolism, making it a promising candidate for the development of new treatments for diabetes.
Used in Anti-Microbial Applications:
2',4'-DIHYDROXY-2-METHOXYCHALCONE is used as an anti-microbial agent, as it has been shown to possess anti-bacterial and anti-fungal properties, making it a potential candidate for the development of new antimicrobial drugs.
Used in Anti-Inflammatory Applications:
2',4'-DIHYDROXY-2-METHOXYCHALCONE is used as an anti-inflammatory agent, as it has been shown to possess anti-inflammatory properties, making it a potential candidate for the development of new treatments for inflammatory conditions.

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 135-02-4 ortho-anisaldehyde 
• 1026847-36-8 (E)-1-[2-Hydroxy-4-(tetrahydro-pyran-2-yloxy)-phenyl]-3-(2-methoxy-phenyl)-propenone 
• 111841-07-7 2-hydroxy-4-(tetrahydropyran-2-yloxy)acetophenone 
• 22877-01-6 2,4-bis(benzyloxy)acetophenone 

Downstream Products

• 686717-90-8 1-[3-(2,4-dihydroxy-phenyl)-5-(2-methoxy-phenyl)-4,5-dihydro-pyrazol-1-yl]-ethanone 

Relevant academic research and scientific papers

Design, synthesis and SAR study of hydroxychalcone inhibitors of human β-secretase (BACE1)

According to the structural characteristics of isoliquiritigenin from Glycyrrhiza uralensis, a series of hydroxychalcones has been designed, synthesized and evaluated for their in vitro inhibitory activities of β-secretase (BACE1). Structure-activity relationship study suggested that inhibitory activity against BACE1 was governed to a greater extent by the hydroxyl substituent on A-and B-ring of the chalcone, and the most active compound was substituted with four hydroxyl group (17, IC50=0.27 μM).

Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein

A series of substituted pyrazolines were synthesized and evaluated for their anticancer activity and for their ability to inhibit P-glycoprotein- mediated multidrug resistance by direct binding to a purified protein domain containing an ATP-binding site and a modulator interacting region. Compounds 2a and e have been found to bind to P-glycoprotein with greater affinity.

Synthesis and Selective Inhibitory Activity of 1-Acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole Derivatives against Monoamine Oxidase

A novel series of 1-acetyl-3-(4-hydroxy- and 2,4-dihydroxyphenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole derivatives 1 - 12 have been synthesized and investigated for the ability to selectively inhibit the activity of the A and B isoforms of monoamine oxidase

Synthesis and activity of a new series of chalcones as aldose reductase inhibitors

A new series of chalcone derivatives has been synthesized and tested in vitro in order to assess their ability to inhibit aldose reductase enzyme (ALR2) and their specificity towards the target enzyme with respect to other oxidoreductases, such as aldehyde reductase, sorbitol dehydrogenase, and glutathione reductase. All the compounds display affinity for ALR2. The X-ray crystal structure of 1-(2,4-dihydroxyphenyl)-3-(2-methoxyphenyl)propen-1-one was determined.

Studies in cell suspension cultures of cassia didymobotrya. Part VI. The biotransformation of chalcones to aurones and auronols

Cell-free extracts derived from tissue cultures of Cassia didymobotrya, which previously had been reported to convert 4-hydroxychalcones to flavones and biflavanones, catalyze the biotransformation of 2-hydroxychalcones to aurones and auronols. The aurone